http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
권정현,장홍래,성제중,안형근,장순재,송문호 한국비파괴검사학회 2003 학술대회 논문집 Vol.- No.1
The nondestructive testing using ultrasonic pulse-echo data is an effective test methodology esperially for metal structure. Typically, the ultrasonic pulse-echo data is processed and the results are shown in A-scan, B-scan or C-scan formats. Upon viewing B-scan and C-scan data the viewer is able to identify the location of faults as well as their rough dimension. In this paper, we evaluate the applicability of various 3-D visualization methods frequently used in medical imaging, namely, surface rendering (SR), volume rendering (VR) and maximum intensity projection (MIP), for nondestructive testing purposes. Such 3-D visualization of ultrasonic pulse-echo data enables easier identification of the location and dimension of faults more accurately.
Pharmacokinetics of a new antitumor 3-arylisoquinoline derivative, CWJ-a-5
Kim, Ki-Eun,Cho, Won-Jae,Chang, Soon-Jae,Yong, Chul-Soon,Lee, Chi-Ho,Kim, Dae-Duk 영남대학교 약품개발연구소 2001 영남대학교 약품개발연구소 연구업적집 Vol.11 No.-
1-(4-Methylpiperazinyl)-3-phenylisoquinoline hydrochloride (CWJ-a-5) is newly developed from benzo[c]phenanthridine alkaloids and derivative and has exhibited potend potent antitumor activities, in vitro and in vivo. The pharmacokinetics of this novel antitumor 3-arylisoquinoline derivative was studied after intravenous (iv). oral (po) and hepatoportal (pv) administration in rats. A simple high performance liquid chromatographic method was developed to determine the concentrations of CWJ-a-5 in plasma, bile and urine. Plasma concentration profiles of CWJ-a-5 were best fitted by the two-compartment model after iv administration and showed a linear pharmacokinetic behavior up to 20 mg/kg doses. The half-life of CWJ-a-5 in the post-distributive phase ????????. total-body plasma clearance (CL_(1)), and volume of distribution at steady-state (Vd_(ss)) were 86.9 min, 5.72 l/h per kilogram and 9.79 l/kg, respectively, after iv administration of 10 mg/kg. Biliary and urinary excretion of CWJ-a-5 was < 1% after iv injection of 10 mg/kg. The bioavailability of CWJ-a-5 after po and pv administration (50 and 10 mg/kg, respectively) was 52.9 and 72.2%, respectively. Gastrointestinal bioavailability was calculated to be 73.3%. The apparent partition coefficient (log p) of CWJ-a-5 between n-octanol and water was 2.64. Plasma protein binding of CWJ-a-5 measured by the ultrafiltration method was > 95%. ⓒ 2004 Elsevier Science B.V. All rights reserved.